Kilitch Drugs (india) Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Kilitch Drugs (india) Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $1.6M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Kilitch Drugs (india) Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $1.6M Trade | TransData Nexus

Kilitch Drugs (india) Limited

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $1.6M Total Trade · DGFT Verified

Kilitch Drugs (india) Limited is an Indian pharmaceutical exporter with a total trade value of $1.6M across 2 products in 1 therapeutic categories. Based on 49 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Piperacillin ($1.5M), Ceftazidime ($150.0K), .

Kilitch Drugs (india) Limited — Export Portfolio & Destination Treemap

Kilitch Drugs (india) Limited pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Kilitch Drugs (india) Limited? — Company Overview & Market Position

Kilitch Drugs (India) Limited, established in 1978 by the late Mr. Pratap Mehta, is a prominent Indian pharmaceutical company specializing in the development, manufacturing, and marketing of a diverse range of pharmaceutical formulations. The company offers products in various dosage forms, including solid, liquid, and parenteral forms, catering to both domestic and international markets. Headquartered in Mumbai, Maharashtra, India, Kilitch Drugs is publicly listed on the Bombay Stock Exchange (BSE) under the ticker symbol 524500 and on the National Stock Exchange of India (NSE) under the ticker symbol KILITCH. As of March 13, 2026, the company's market capitalization was approximately ₹5.54 billion, with a revenue of ₹2.07 billion for the fiscal year ending March 31, 2025. The company employs around 187 individuals, reflecting a growth of 11.31% in its workforce over the past year. For more information, visit their official website at kilitch.com.

What Does Kilitch Drugs (india) Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Piperacillin$1.5M 2

Product Portfolio — Top 2 by Export Value

Kilitch Drugs (india) Limited exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Piperacillin	Advanced Antibiotics	$1.5M	46	1.2%	8
2	Ceftazidime	Advanced Antibiotics	$150.0K	3	1.4%	7

Kilitch Drugs (india) Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $1.6M. The top category is Advanced Antibiotics (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Kilitch Drugs (india) Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Kilitch Drugs operates multiple manufacturing facilities to meet the growing demand for its pharmaceutical products. The Mumbai Unit is equipped with advanced facilities designed for the production of high-precision pharmaceutical products, including sterile preparations such as dry powders for injection (DPI), small volume parenterals (SVP) in ampoules and vials, as well as ophthalmic and nasal solutions, ensuring compliance with global Good Manufacturing Practice (GMP) standards. Additionally, the company has a plant in Pen, Maharashtra, which is currently under construction and is expected to be fully operational by the end of the fiscal year 2025-2026. This facility is designed to meet international regulatory standards, including WHO, EU, and USFDA GMP, and will focus on manufacturing nutraceuticals, injectables, ophthalmic products, and oral solid dosage forms.

3Key Leadership

The leadership team at Kilitch Drugs (India) Limited is headed by Chairman and Managing Director Mukund P. Mehta, who brings extensive experience to the company. Other key executives include Bhavin M. Mehta, Whole-Time Director and Executive Director, and Mira Mehta, Managing Director. The board also comprises independent non-executive directors such as Venkita Subramanian Rajan and Dipen Jayantilal Jain, who provide strategic guidance and oversight.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Kilitch Drugs (india) Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Kilitch Drugs (India) Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities adhere to international standards, with approvals from regulatory bodies such as the World Health Organization (WHO) for Good Manufacturing Practice (GMP) and the U.S. Food and Drug Administration (FDA). These certifications facilitate market access and ensure compliance with stringent quality standards. The company's product portfolio includes a range of parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops, catering to various therapeutic areas.

2Emerging Markets

Kilitch Drugs (India) Limited has expanded its footprint into emerging markets, including Africa, Latin America, and Southeast Asia. The company's manufacturing facilities in Ethiopia, for instance, produce a wide range of cephalosporin products, including tablets, capsules, injectables, dry powders for suspension, and syrups. This facility aims to lead in the African markets, fulfilling local demand for high-quality generics previously imported from other countries. Additionally, the company's products are available in various countries across Africa, Latin America, and Southeast Asia, indicating a broad international presence.

Geographic Strategy

Kilitch Drugs (india) Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Kilitch Drugs (India) Limited's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA), ensuring compliance with U.S. regulatory standards. The company's product portfolio includes a range of parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops, catering to various therapeutic areas. These products are designed to meet the quality and safety standards required for the U.S. market.

2WHO & EU GMP

Kilitch Drugs (India) Limited's manufacturing facilities are certified by the World Health Organization (WHO) for Good Manufacturing Practice (GMP), ensuring adherence to international quality standards. The company's products are also manufactured in compliance with European Union (EU) GMP standards, facilitating market access in EU member countries. These certifications reflect the company's commitment to maintaining high-quality manufacturing processes.

3CDSCO & Indian Regulatory

Kilitch Drugs (india) Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Kilitch Drugs (India) Limited operates in a competitive pharmaceutical industry, facing competition from both domestic and international companies. The company's focus on manufacturing a diverse range of pharmaceutical formulations, including parenteral, nasal, and topical products, positions it to compete effectively in various therapeutic areas. While specific market share data is not available, the company's strategic initiatives, such as expanding manufacturing capabilities and obtaining international certifications, enhance its competitive position.

2Key Differentiators

Kilitch Drugs (India) Limited differentiates itself through its extensive experience in the pharmaceutical industry, with over 47 years of expertise. The company's commitment to quality is demonstrated by its WHO-GMP certified manufacturing facilities and adherence to international standards. Additionally, Kilitch Drugs offers a broad product portfolio, including cephalosporins, antimalarials, and ophthalmic and nasal products, catering to a wide range of therapeutic areas.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Kilitch Drugs (india) Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Kilitch Drugs (India) Limited has a track record of consistent export activity, with a total export value of $1.6 million USD and 49 shipments across two products in one therapeutic category. The company's top products include Piperacillin and Ceftazidime, with market shares of 1.2% and 1.4%, respectively. This indicates a focused product portfolio with a concentration on advanced antibiotics. The company's adherence to international quality standards, as evidenced by its WHO-GMP certifications, underscores its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Registration: Confirm the company's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA).

WHO-GMP Certification: Ensure the manufacturing facilities are certified by the World Health Organization for Good Manufacturing Practice.

Frequently Asked Questions — Kilitch Drugs (india) Limited

How many pharmaceutical products does Kilitch Drugs (india) Limited export from India?

Kilitch Drugs (india) Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Piperacillin ($1.5M), Ceftazidime ($150.0K). Total export value is $1.6M.

What is Kilitch Drugs (india) Limited's total pharmaceutical export value?

Kilitch Drugs (india) Limited's total pharmaceutical export value is $1.6M, based on 49 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Kilitch Drugs (india) Limited cover?

Kilitch Drugs (india) Limited exports across 1 therapeutic categories. The largest are Advanced Antibiotics (100.0%, 2 products).

Get Full Kilitch Drugs (india) Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.